Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew H Ko, M.D.
University of California, San Francisco
Principal Investigator - Li-Tzong Chen, M.D.
National Health Research Institutes, Taiwan
Principal Investigator - Yu-Lin Lin, M.D.
National Taiwan University Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Health Research Institutes/national Chen-Kung Uiversity Hospital
Tainan, Taiwan
- National Taiwan University Hospital
Taipei, Taiwan
- Comprehensive Cancer Center, Ucsf
San Francisco, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2009
- Primary completion
- 31 Dec 2010
- Completion
- 31 Jul 2012
- Last update posted
- 6 Sept 2019
- Registered enrollment
- 41
- Registry id
- NCT00813163
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.